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TITLE OF CASE 
Bilateral primary renal diffuse large B-cell lymphoma: a rare presentation of 
paediatric renal disease mimicking juvenile nephronophthisis 
SUMMARY 
A 12 year old boy presented with a prolonged history of headache, fatigue, and 
hypertension. Initial investigations were consistent with presumed non-oliguric end 
stage renal disease, leading to a provisional diagnosis of juvenile nephronophthisis. 
Subsequent imaging demonstrated bilaterally enlarged kidneys without cystic 
change. Mutation analysis was negative for nephronophthisis, causing diagnostic 
uncertainty which prompted renal biopsy. Histology revealed a primary renal diffuse 
large B-cell lymphoma (PRL) which was highly responsive to chemotherapy 
including the anti-CD20 monoclonal agent, rituximab. Renal function improved during 
lymphoma treatment, with residual chronic kidney disease stage 3a once 
chemotherapy was completed. Atypical diagnostic features should always prompt re-
evaluation of a patient. In this case, the delayed malignancy diagnosis did not have 
an adverse effect on patient survival or morbidity. The outcome for PRL has 
improved markedly following the introduction of rituximab. 
BACKGROUND 
Juvenile nephronopthisis is an uncommon but important cause of end stage renal 
disease (ESRD) in the paediatric population. Classically, children present in early 
adolescence with the biochemical features of ESRD – elevated urea, creatinine, 
elevated parathormone, anaemia of chronic disease, but often with a normal blood 
pressure and bland urine (no haematuria or cellular elements with minimal 
proteinuria). The commonest mutation, NPHP1, accounts for approximately 85% of 
cases. Histological confirmation by renal biopsy is not required in the presence of 
classic symptoms and confirmatory genetic testing. We describe an adolescent male 
with a ‘classic’ clinical presentation, in whom subsequent identification of atypical 
features prompted biopsy which revealed an extremely rare malignancy. This 
facilitated prompt treatment and resulted in an improvement in renal function with 
complete remission of malignancy. 
CASE PRESENTATION 
A 12-year-old boy was referred by his primary care physician with a 6-8 week history 
of progressive malaise, daily generalised headache associated with wakening from 
sleep, persistent nausea with vomiting, and a reduced appetite. He had polydipsia 
and polyuria including nocturia and nocturnal drinking, and also reported a two year 
history of poor weight gain. A casual blood pressure on admission was 169/111 
mmHg (>99th centile for age, gender and height). There was no other past medical 
history. Both parents and an older sister had a background of significant anxiety 
and/or depression, partly related to an eviction and temporary homelessness several 
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years previously. There was no family history of renal disease or other physical 
illness. 
Examination showed a pale, slim and sallow boy with height 0.4th centile and weight 
2nd centile. No previous growth measurements were available. Repeat blood 
pressure readings stabilised to 130-140/90-100mmHg (>99th centile for age, gender 
and height). Abdominal palpation suggested enlarged ballotable kidneys without 
other organomegaly. There was no evidence of peripheral oedema or ascites. 
Fundoscopy was normal.
INVESTIGATIONS If relevant 
Initial investigations revealed marked renal dysfunction with a normocytic anaemia, 
normal platelets and a preserved white cell count: creatinine 647mol/l (7.31mg/dL), 
urea 39.2mmol/l (109.8mg/dL), potassium 6.0mmol/L, parathormone 25.2pmol/L 
(252pg/ml), haemoglobin 8.1g/dL, platelets 210x109/L, white cell count 7.6 x109/L. 
Lactate dehydrogenase was mildly elevated at 285 U/L and urate was normal at 371 
umol/L (6.3mg/dL). Urinalysis demonstrated no haematuria with only 1+ proteinuria. 
A formal urine protein:creatinine ratio was 49mg/mmol (434mg/g). 
Immunology investigations were all negative (table 1). Epstein Barr virus PCR and 
Immunoglobulin G to EBV antigens were negative, confirming no current or prior 
exposure. 
Investigation Result
Anti-Nuclear Antibody (ANA) Negative
Antineutrophil Cytoplasmic Antibodies (ANCA) Negative
DNA antibodies 0.9 IU/ml  -  Normal
Anti-glomerular basement membrane antibodies (GBM) <0.8 Units - Normal
C3 108 mg/dL (80 - 170)
C4 35 mg/dL (14 - 44)
Table 1: Immunology investigations 
Abdominal ultrasound demonstrated bilaterally enlarged kidneys, 12.6cm right, 
11.9cm left (both >99th centile) with loss of corticomedullary differentiation, patchy 
increased parenchymal echogenicity and mild left sided hydronephrosis (Figure 1). 
There were no cystic or focal changes and no lymphadenopathy. 
Magnetic resonance angiography was undertaken as part of a pre-transplant 
assessment. This confirmed abnormal enlarged kidneys and found bilateral 
hydronephrosis (Figure 2). 
Given the absence of cystic change classically seen in advanced nephronophthisis, 
the history and imaging was re-visited. The presentation with hypertension was also 
somewhat atypical though blood pressure responded well to amlodipine, and 
psychological assessment confirmed an element of anxiety. Headaches remained an 
issue despite excellent blood pressure control, suggesting they were not solely a 
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symptomatic manifestation of hypertension.  In an effort to avoid renal biopsy 
associated with a greater rate of complications, genetic analyses were expedited for 
abnormalities in the NPHP1 gene. Though NPHP1 mutations are only responsible 
for 85% of cases, it was agreed that genetic confirmation would be sufficient to avoid 
a biopsy given evidence to suggest ESRD at presentation. Analysis was available 
one month later, with no evident mutation in NPHP1. Limitations and risks of renal 
biopsy were discussed with the family, including insufficient tissue, reduced 
likelihood of diagnostic tissue and increased risk of complications notably 
haemorrhage in biopsy from a kidney with advanced disease. A percutaneous 
needle biopsy was performed without incident. Histological examination 
unexpectedly revealed diffuse infiltration of undifferentiated highly abnormal cells 
with minimal cytoplasm and large, variably shaped nuclei consistent with either a 
high-grade lymphoma or sarcoma. Further cell typing confirmed the tumour 
expressed the B cell markers CD20, CD79a and bcl6. Myc protein was expressed in 
less than 5% of the cells. Ki67 was 100% positive indicating a high proliferation rate. 
Tdt, CD10, bcl2, CD3, cyclin D1, MUM1, ALK1 and CD5 were negative; in-situ 
hybridisation for EBV was negative. The immunophenotype was consistent with a 
high grade non-Hodgkins B-cell lymphoma. A bone marrow biopsy, lumbar puncture 
and whole-body MRI displayed no evidence of extra-renal disease supporting a 
diagnosis of bilateral primary renal lymphoma (PRL). 
DIFFERENTIAL DIAGNOSIS 
This case at initial presentation (prior to imaging) was very classical for juvenile 
nephronophthisis. Nephronophthisis is the commonest monogenic cause of end 
stage renal disease in children and adolescents. An autosomal recessive ciliopathy, 
it is characterised by a tubulo-interstitial nephropathy in isolation or as part of a 
ciliopathy syndrome with extra-renal manifestations in around 20% of cases (eg 
Senior-Loken, Joubert). [1] Large scale deletions in the NPHP1 gene account for 
around 85% of cases with isolated renal disease in the commonest subtype, juvenile 
nephronophthisis (NPHP type 1). [2] 
In juvenile nephronophthisis, end stage renal disease (ESRD) develops at a median 
age of 13 years, though symptoms of polyuria and polydipsia can begin insidiously 
as early as 6 years of age and will predate declining glomerular filtration rate (GFR), 
anaemia and growth restriction. Hypertension is uncommon even in advanced 
disease due to a urinary concentrating defect. [3] Ultrasound usually demonstrates 
normal or small-sized kidneys with increased echogenicity and loss of 
corticomedullary differentiation. Cysts are often absent on initial scans though 
develop as the disease progresses. Hydronephrosis is not a characteristic feature. 
[4] 
The presence of bilateral nephromegaly, stage 2 hypertension (systolic and/or 
diastolic BP ≥ 95th centile) mild-moderate hydronephrosis, and negative genetic 
analyses all combined to cause pause. Other important causes of bilateral 
nephromegaly were all considered and discounted. Autosomal dominant polycystic 
kidney disease (ADPKD) can rarely present in early adolescence with progressive 
renal failure, enlarged kidneys, hypertension and a urinary concentrating defect. 
Advanced cystic changes are established before any significant decline in GFR, and 
a positive family history supports the diagnosis. Haematuria (sometimes secondary 
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to cystic haemorrhage) and proteinuria are typical in advanced disease. [5] The 
absence of cystic change on ultrasound made a different cystic renal disease highly 
unlikely. 
Tuberous sclerosis complex (TSC) may present with enlarged kidneys, renal 
impairment and hypertension in association with extensive bilateral 
angiomyolipomas. The risk of renal cell carcinoma and oncocytoma is also increased 
and can present bilaterally. Cystic changes are present in 50% and rarely can reflect 
a contiguous gene syndrome involving genes associated with ADPKD. ESRD is 
uncommon in early adolescence. [6] Other syndromic features are often present, 
particularly neuro-cutaneous stigmata. The imaging was not consistent with the 
typical appearance of angiomyolipomata, nor were there any other associated 
features. 
Wilms tumour is the commonest paediatric renal malignancy affecting around 1 in 
10,000 children. It is associated with renal enlargement and the presence of 
embryonal precursor lesions termed nephrogenic rests, with bilateral disease in 5-
8%. [7]ESRD is uncommon with the exception of patients with WAGR syndrome, 
associated genito-urinary abnormalities, or where significant surgical removal of 
renal tissue has been necessary. [8] 
Nephromegaly may also occur in children with overgrowth syndromes such as 
Beckwith-Wiedemann (BWS) and Simpson-Golabi-Behmel syndrome (SGB), and is 
particularly common in Perlman syndrome[9].  A genetic aetiology underlies many of 
these conditions, usually affecting the cell cycle directly or related modifying factors, 
and there is often an increased risk of associated malignancy.
Further causes of bilateral nephromegaly in association with ESRD include 
secondary renal infiltration by a haematolymphoid malignancy or deposition 
disorders such as sarcoidosis and amyloidosis. The two year history of poor weight 
gain, and notably reduced height was felt initially to make a diagnosis of malignancy 
highly unlikely, but would be consistent with the development of progressive renal 
dysfunction. 
The confirmed diagnosis of primary renal lymphoma was surprising given the above, 
but had characteristic histological findings in the absence of evidence of extra-renal 
disease. 
TREATMENT 
In view of the significant lymphoma burden, tumor lysis syndrome was felt to 
represent a very real risk, particularly in the context of severe renal dysfunction. 
Prophylactic continuous veno-venous haemofiltration (CVVH) was commenced 
shortly before the administration of the first dose of corticosteroids, and continued for 
48 hours with no significant elevation in potassium, phosphate, or urate. Imaging 
immediately following this already demonstrated a significant reduction in renal size 
bilaterally to 10.4cm on the right, 10.2cm on the left (95th centile), and CVVH was 
discontinued. Chemotherapy was then intensified consisting of a 21 day cycle 
combining cyclophosphamide, doxorubicin and vincristine with prednisolone and the 
anti-CD20 monoclonal antibody Rituximab (R- CHOP), for a total of six cycles. 
Page 4 of 19
Intrathecal chemotherapy consisting of cytarabine and hydrocortisone or cytarabine 
and methotrexate was administered with cycle 2, 4 and 6. Intravenous methotrexate 
was not given due the creatinine clearance of <30ml/min. Nutritional support was 
needed via a naso-gastric tube, with supplemental feeds suitable for patients with 
marked renal dysfunction. At no point during the subsequent chemotherapy was any 
additional renal support required.
OUTCOME AND FOLLOW-UP 
His initial chemotherapy cycle was complicated with episodes of febrile neutropenia, 
severe mucositis and neutropenic sepsis secondary to a suspected Pneumocystis 
jirovecii pneumonia. He developed an acute kidney injury most likely due to a 
combination of nephrotoxic antibiotics and challenging fluid management during this 
period. He had a prolonged in-patient stay with an episode of confirmed fungal 
sepsis, and a temporary loss of vision lasting <72 hours, which remains unexplained. 
Follow up imaging demonstrated a good chemotherapy response with ongoing 
reduction in kidney size, improved corticomedullary differentiation and reduced 
echogenicity. The hydronephrosis resolved, suggesting that tumour infiltration may 
have impacted on upper tract drainage, with no recurrence of hydronephrosis on all 
subsequent imaging. This all coincided with improving renal function. Six months 
following the initiation of chemotherapy with completion of the final cycle, ultrasound 
demonstrated small kidneys, 5.7cm right (<0.4th centile), 8.1cm left (0.4th centile) with 
cortical scarring on the right and two identifiable masses suspected to be renal 
pseudotumours. Functional imaging confirmed much poorer overall right sided 
function (16% right, 84% left). Further imaging demonstrated an increased size of 
the ‘pseudotumours’, so a right open wedge renal biopsy was undertaken to 
guarantee obtaining diagnostic tissue. This showed typical ‘end-stage’ features 
including sclerosed renal parenchyma. There was no evidence of B-cell lymphoma 
recurrence. Renal function is stable nine months after completion of chemotherapy 
with a serum creatinine of 100-120mol/L (1.13 - 1.36 mg/dL), estimated glomerular 
filtration rate of 55ml/min/1,73m2. He remains in remission requiring no medications, 
though supplemental feeding via gastrostomy to support weight gain is ongoing, as 
is psychological support. 
DISCUSSION 
This is an unusual case of primary renal lymphoma presenting in a child with 
hypertension and headaches. His symptoms were initially attributed to significant 
renal dysfunction presumed to reflect end stage renal disease given evidence of 
anaemia, hyperparathyroidism and growth retardation. The presence of features 
inconsistent with juvenile nephronophthisis (enlarged kidneys, hypertension), 
prompted further investigation which revealed the diagnosis. One additional 
hypothesis is that the presence of residual small kidneys following treatment could 
have reflected an underlying structural renal disease/dysplasia which was at 
increased risk for malignant change. 
Primary renal lymphoma (PRL) is defined as non-Hodgkin’s lymphoma originating 
directly from within renal tissue without systemic involvement. It is a rare 
presentation, accounting for <1% of all extranodal lymphoma. [10] Several proposed 
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diagnostic criteria exist though there is broad consensus on three key features: 1. 
Presence of histologically confirmed lymphomatous renal infiltration 2. Renal 
enlargement without obstructive features 3. Absence of extra-renal lymphoma at 
presentation (See Table 2) [11,12] 
Malbrain Criteria [12] Stallone Criteria [11]
1. Histological confirmation 1.Lymphomatous renal inflammation
1. Enlarged kidney without obstruction 2. Enlarged kidneys without obstruction
2. No nodal or extranodal lymphoma 3.No extra renal lymphoma at diagnosis
3. Renal disease unattributable to other causes
4. Improvement in renal function after treatment
Table 2: Proposed diagnostic criteria for Primary Renal Lymphoma 
Whether PRL is a true disease entity has been questioned due to the widely held 
view that renal parenchyma lacks lymphatic tissue. [13] Subsequent case series 
support the view that PRL exists as opposed to reflecting secondary infiltration from 
an occult primary. [11,14] Proposed explanatory mechanisms include locally invasive 
lymphoma originating in the renal capsule rich in lymphatics, or the malignant 
transformation of lymphoid tissue arising within the renal parenchyma as a 
consequence of chronic inflammation. [15,16] More recently, using RNA sequencing 
of single cells Stewart et al have demonstrated that lymphatic cells are identifiable 
within the fetal kidney from the first trimester. [17] 
Presentation is usually unilateral, with bilateral disease usually reported at 10-20% 
[11] (though a recent population based analysis reported bilateral disease in only 
2.7% of 559 cases with a median age of 72 at presentation) [18]. The commonest 
presenting symptoms include flank pain and an abdominal mass alongside classical 
“B” symptoms of fevers, fatigue, weight loss and night sweats. [14,16,19] Abnormal 
urinalysis is rare and hypertension is variable. [16,19] Renal impairment as a 
consequence of tumour infiltration commonly accompanies bilateral disease though 
has been reported in unilateral presentations. [20] The commonest histological 
subtype matches the diffuse large B-cell variant in our case [13] though ultrasound 
more typically shows hypo /anechoic changes. [20,21]
Survival data suggests two disease epochs. A 2016 review of all available reported 
cases of PRL from 1989 calculated a mean survival time of 21 months for bilateral 
PRL and 68 months for unilateral PRL. [22] Prior to the introduction of rituximab, 
PRL conferred a very poor prognosis. Recent reports indicate that PRL is often 
highly sensitive to anti-CD20 therapy, with not a single death reported since 
rituximab became commercially available. [23–25]
At the time of writing there are 34 cases which are identifiable as or reported as PRL 
in children in the literature (see Table 3). Applying the less stringent Stallone criteria, 
[11] 10 cases where extra renal disease was identified at presentation can be 
excluded, leaving 24 cases with a median age of 6 at presentation. Of these, 16 
cases (67%) were B-Cell in origin (including 5 cases of Burkitt’s lymphoma), 6 (25%) 
were T-Cell in origin, with 2 (8%) cases reporting indeterminate histology. In contrast 
to reported literature involving adult populations, 20 cases (83%) had bilateral 
disease at presentation. 11 cases (46%) had acute renal impairment at presentation, 
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all of which had bilateral disease. 11 patients (46%) were in remission at the time of 
publication, 8 (33%) had died, 1 case (4%) was lost to follow up and the remaining 4 
cases (17%) did not report outcomes. 
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Primary Renal Lymphoma - Paediatric Case Reports
Included
N Age Yr Sex Side Histology Symptoms HTN ARF Extra-renal Disease Anaemia Urinalysis Therapy Outcome Ref
1 12 1974 M R B-cell 
(Burkitt’s)




2 14 1983 M B Unknown Vomiting, flank pain, 
polyuria, polydipsia
N Y N N 1+ protein Radiotherapy Not reported [27]
3 3 1986 F B T-Cell Adbo mass Y Y N N ? Chemotherapy NOS, 
Radiotherapy
Remission [28]
4 4 1989 M B T-Cell ? ? ? N ? ? Chemotherapy NOS Remission [29]
5 10 1991 M B T-Cell Abdo mass Y Y N N ? Chemotherapy NOS Remission [30]
6 2 1993 F B B-Cell Vomiting, Abdo 
distention
N N N Y ? None Died [31]
7 5 1994 F B B-Cell Fever, weight loss, 
night sweats
? N N Y ? m-BACOD Died [32]
8 4 1994 M B B-Cell Fever, nausea, 
vomiting
? N N N ? LSA2-L2 Died [33]
9 6 1995 M L B-Cell Painless haematuria ? N N ? ? NHL-902 Remission [34]
10 3 1996 M B B-Cell Fever, vomiting, 
anorexia
? Y N N Negative POG Protocol 9317 Remission [35]
11 11 1997 F B B-Cell Anorexia, vomiting, 
fatigue, weight loss
Y Y N Y 2+ protein NHL-B 93 Died [36]
12 15 1997 F B B-Cell Abdominal mass ? N N Y ? Chemotherapy NOS Died [37]
13 12 2004 M B B-Cell 
(Burkitt’s)
? ? ? N ? ? ? Not reported [38]
14 2 2006 M B T-Cell Abdo distention ? Y N Y ? cyclophosphamide, 
Vincristine, Prednisolone, L-
asparaginase
Lost to follow 
up
[39]
15 5 2007 F B T -Cell Nil Y N N N Trace protein CCG1961 Died [40]
16 12 2010 F B B-Cell 
(Burkitt’s)
? ? Y N Y Negative LNH B0 Not reported [41]
17 12 2010 M R B-Cell Abdominal mass ? N N ? ? Berlin-Frankfurt-
Munster 90 protocol
Remission [42]
18 2 2010 F B T-Cell Fever, abdo 
distention







19 7 2011 F B Unknown Fever, joint pain, 
abdo distention
? N N Y Negative CHOP Not reported [44]
20 4 2015 M B B-Cell Abdo distention, N Y N N 1+ Protein FAB-LMB 96 Remission [45]
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(Burkitt’s) fever
21 8 2015 ? B B-Cell Fever, joint pain ? N N Y Trace protein R-CHOP Remission [46]
22 10 2017 M L B-Cell Abdominal mass ? N N N ? Nephrectomy, NHL-
BFM 95
Died [47]
23 4 2018 M B B-Cell Fatigue N Y N Y Negative R-CHOP Remission [48]
24 4 2018 M B B-Cell 
(Burkitt’s)
? ? Y N ? ? None Died [49]
Excluded
N Age Yr Sex Side Histology Symptoms HTN ARF Extra-renal Disease Anaemia Urinalysis Therapy Outcome Refl is se i
25 4 2012 F B B-Cell Abdo distention, 
headache
N N CNS ? ? NHL-BFM 95 Died [50]
26 14 2002 M B B-Cell Flank pain, headache Y Y Bone N 2+ protein CCG-5942 Remission [51]
27 3 2008 M B B-Cell Abdo distention, 
pain, fever
Y N Orbit Y ? BFM-90 Died [52]
28 6 1997 F B T-Cell Abdo pain, fever N Y Lung, choroid plexus Y ? None Died [53]
29 4 1997 M R T-Cell Abdo distention, 
vomiting
? N Local lymph nodes ? ? CHOP Remission [54]
30 6 1973 M B ? Anorexia Y Y Tonsils Y Negative Vinc, Dactin, 
Radiotherapy
Not reported [55]
31 6 1994 M B T-Cell Anorexia, weight loss, 
fatigue, abdo pain
? Y Bone Marrow N ? ALL protocol Remission [56]
32 12 2013 F R B-Cell Gross Haematuria ? N Thyroid N Negative Nephrectomy, 
Chemotherapy NOS
Remission [57]




N Y CNS Y 1+ Protein None Not reported [58]
34 4 1995 M R B-Cell Calf pain, shoulder 
pain
? ? Bone N ? Nephrectomy Not reported [59]
Table 1: Primary Renal Lymphoma: Paediatric Cases
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LEARNING POINTS/TAKE HOME MESSAGES 
 This is a case in which inconsistent features of an initially classic presentation 
of a rare condition prompted further investigation to elicit the diagnosis. 
 Careful clinical evaluation is essential in patients presenting with presumed 
“ESRD”. Patients should be thoroughly investigated for potentially reversible 
causes.  The presence of nephromegaly requires extensive assessment, 
which may include  a renal biopsy where the underlying diagnosis is unclear.
 Juvenile nephronophthisis typically presents in end stage renal disease in 
early adolescence with normal blood pressure and normal to small sized 
kidneys 
 Primary renal diffuse large B-cell lymphoma is an extremely rare paediatric 
presentation but reminds that clinical presentation with a treatable malignancy 
may also be highly variable. Bilateral nephromegaly should always prompt 
consideration of malignancy. 
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FIGURE/VIDEO CAPTIONS 
Figure 1.1: Renal Ultrasound – Right Kidney 
Figure 1.2: Renal Ultrasound – Left Kidney 
Figure 2: Magnetic Resonance Angiogram 
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PATIENT’S PERSPECTIVE 
Everything that has happened to me came as a shock to me, my family and friends. It all started 
with a sickness bug that got worse every day and I got sent home from school. My dad took me to 
the doctors who tested my blood pressure which was very high and recommended I go to hospital. 
My mum took me to the hospital where I had some blood tests done. This got me worried but 
then I met a doctor who was very nice and funny which calmed me down. He then told me the 
results of the blood tests and they weren’t good. He told me I had kidney disease. As soon as he 
told I broke down in tears. 
It took a few weeks of tests and scans before the cause of the kidney failure was discovered and 
that reason was cancer. This devastated my whole family but thanks to the doctors we were 
convinced I could beat cancer and return to full health. It took a long and painful 6 months but I 
beat cancer. When we found out it was gone it was the happiest day of my life. I am now a year in 
remission and my kidney function has returned to a working function. I will probably still need a 
transplant in the future but my dad put himself through painful weight loss surgery to allow him to 
give me one and I can’t thank him enough for that. It has been a long journey with a way to go but 
I would like to tell anyone going through life-threatening illness to never give up and stay positive. 
I hope you get doctors as good as mine who refused to give up on me and worked very hard to 
return me to health, especially my main consultants, but special thanks also go to the nurses of 
the kidney and cancer wards who looked after me daily and always managed to cheer me up when 
I was down and to my family who were with me every day. I thank you all. 
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Figure 2: Magnetic Resonance Angiogram 
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Figure 1.1: Renal Ultrasound - Right Kidney 
Figure 1.2: Renal Ultrasound - Left Kidney 
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